MiR-106b significantly decreased the ATP-binding cassette transporter A1 (ABCA1) levels and impaired cellular cholesterol efflux in neuronal cells (Kim et al., 2012), targets TGF-β type II receptor (Tβ R II) to affect TGF-β signaling, thereby contributing to the pathogenesis of AD (Wang et al., 2010). Here, ABCA1 is linked to Alzheimer disease.